CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 2,103 enrolled
Drug / intervention
cCTA with selective FFRctother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03702244
NCT03702244N/ACompleted
CompareCT.gov

Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization

HeartFlow, Inc.·interventional·Posted Oct 11, 2018·Updated Dec 29, 2023

In Brief

A clinical study evaluating cCTA with selective FFRct for Coronary Artery Disease. Completed, enrolled 2,103 participants across 1 site.

Detailed Summary

The study will be a prospective, pragmatic, randomized clinical trial of the comparative effectiveness of diagnostic evaluation strategies for stable CAD, to be performed in outpatient settings, including primary care and cardiology practices.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesUnited States
CollaboratorsDuke Clinical Research Institute, Cardiovascular Research Foundation, New York

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedOct 11, 2018
Enrollment StartNov 27, 2018
Primary CompletionMay 20, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.7 years ago

Interventions

cCTA with selective FFRctother

PRECISE will evaluate whether a precision evaluation strategy that combines contemporary risk stratification using the PROMISE Risk Tool with functional and anatomic non-invasive evaluation with cCTA with selective FFRct can improve outcomes over usual care in stable chest pain patients while safely deferring further testing in low-risk patients and reducing cost overall